Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
IndustryARC
www.industryarc.com/
Venkat Reddy
venkat@industryarc.com
(+1) 970-236-3677

Bookmark and Share
Cholera Vaccine Market Size Forecast to Reach $239.6 Million by 2026
Rising Prevalence of Chronic Diseases and Growing Awareness on Immunization Are the Major Factors Driving the Growth of the Market.

BriefingWire.com, 10/11/2021 - [FURL=https://www.industryarc.com/Research/Cholera-Vaccine-Market-Research-506916?utm_source=briefingwire&utm_medium=pressrelease&utm_campaign=paidpressrelease]Cholera Vaccine market[/FURL] size is forecast to reach $239.6 million by 2026, growing at a CAGR of 7.9% during the forecast period 2021-2026. Cholera is caused via the consumption of contaminated food and water by Vibrio Cholerae. It leads to dehydration which in turn may lead to death if not attended properly. It is anticipated to be a global threat to public health that lacks social development and so it is essential to control cholera. Various products that are used for controlling cholera includes Dukoral, Euvichol, Vaxchora, and Shanchol among others. According to international organizations such as WHO, vaccinations have proved to be one of the best methods to treat cholera and has recommended that cholera vaccines should be taken at least 2 weeks gap between the doses.

Key Takeaways

Asia-Pacific dominated the Cholera Vaccine Market in 2020 owing to the increase in the prevalence of cholera disease and rise in the awareness of immunization. The Cholera Vaccine Market scope for different regions will be provided in the final report.

Favorable medical reimbursement policies and growing adoption of combination vaccines in prevention strategies by government are likely to aid the market growth of the Cholera Vaccine Market report.

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Cholera Vaccine Market report.

Lack of proper sanitation and high cost associated with the development of vaccines is poised to create the hurdles for the Cholera Vaccine Market.

Download Sample Report @ [FURL]https://www.industryarc.com/pdfdownload.php?id=506916[/FURL]

Cholera Vaccine Market Segment Analysis – By Geography

Asia Pacific dominated the Cholera Vaccine Market with a major share of 36.5% in 2020. This is attributed to the rising incidences of cholera and rising awareness about immunization. Growing healthcare expenditures, favorable reimbursement policies, and presence of key players is also increasing the growth of the market in this region. However, North America is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the lack of proper sanitation and consumption of contaminated food.

Cholera Vaccine Market Drivers

Increasing Prevalence of Cholera Disease

Rise in awareness of immunization

Cholera Vaccines Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Cholera Vaccines Market. In 2020, the Cholera Vaccines Market share is consolidated by the top ten players present in the market. The Cholera Vaccines Market, top 10 companies are Valneva SE, Sanofi, Johnson & Johnson, Celldex Therapeutics Inc., Merck & Co., GlaxoSmithKline Plc., Emergent BioSolutions Inc., and Astellas Pharma Inc. among others.

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2024 Proserve Technology, Inc.